Biotech stocks have taken a punishing nose-dive over the past month as investors step aside following significant gains. However, the current share slide is likely more a result of emotion than any ...

While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a look at particularly stock-shaking analyst upgrades and downgrades -- just in case ...

Great biotech companies tend to dominate at least one indication. In Biogen's case, that indication is multiple sclerosis. Biogen's Avonex and Tysabri are long-standing blockbuster treatments for ...

Biogen Idec has partnered with Google X, Google's business unit for long-term “moonshot” projects, to study outside factors that might contribute to the progression of multiple sclerosis (MS), ...

This year has turned against biotech investors, as the long-awaited correction came on hard in March and April. While conditions seem to have stabilized for the time being, Biogen Idec remains an ...

) targets: alpha-synuclein, tau and TDP-43. These targets are believed to be relevant for the treatment and prevention of a wide variety of neurodegenerative diseases, including Parkinson's disease, ...

Ahead of the company's earnings announcement, analysts are expecting a positive EPS reading of $1.51/share and revenues of $1.27 billion. Biogen Idec's latest numbers will no doubt be compared with ...

BOSTON, March 24 (Reuters) - Biogen Idec Inc has acquired an option to license the rights to certain experimental cancer drugs being developed by privately held Aveo Pharmaceuticals Inc. Sign up here.

Eight in 10 sectors advanced in the stock market today, as the S&P 500 Index added eight points, or 0.5%, to end at 1,857. The health-care sector again stood out as an underperformer, continuing a ...

Biogen Idec ($BIIB) has struck a far-reaching agreement with CRO giant Quintiles ($Q), tapping the contractor to help design, plan and run its Phase II-IV studies ...

BOSTON, June 10 (Reuters) - Biogen Idec Inc , one of the world's biggest biotechnology companies, said on Tuesday that two proxy advisory firms have recommended that shareholders vote in favor of its ...